预防2型糖尿病 (PHT2) 成人的严重低血糖症:随机对照试验的设计,交付和评估框架
James D Ralston1, Melissa Anderson2, Janet Ng2
1Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA; Washington Permanente Medical Group, 125 16th Ave E, Seattle, WA, USA.
Contemporary clinical trials
|January 22, 2024
概括
这项研究测试了心理教育干预措施,以预防2型糖尿病 (T2D) 的成年人严重低血糖症. 虚拟程序"我的低血糖指南针"旨在减少低血糖事件和相关的医疗保健使用.
科学领域:
- 糖尿病管理 糖尿病管理
- 临床试验中的临床试验.
- 患者教育 患者教育
背景情况:
- 严重的低血糖是糖尿病中降血糖药物的常见并发症.
- 心理教育干预已被证明是有效的预防严重低血糖在1型糖尿病.
- 这项研究调查了高风险的2型糖尿病 (T2D) 的成年人中的疗效.
研究的目的:
- 为了确定心理教育干预措施在减少T2D成年人严重低血糖的有效性.
- 为了比较主动的护士护理管理与没有"我的低压指南针"干预.
主要方法:
- 一项随机对照试验 (PHT2) 涉及T2D的成年人和有严重低血糖或意识受损的病史.
- 参与者被随机分配到接受标准护理或通过"我的虚拟指南针"虚拟精神教育计划增强的护理.
- 主要结局是12个月内自我报告的严重低血糖症.
主要成果:
- PHT2试验旨在比较两种方法的有效性,以减少T2D成年人的严重低血糖症.
- 二次结果包括低血糖意识,对低血糖的恐惧,以及对严重低血糖的医疗利用.
- 过程评估将评估实施的忠实性.
结论:
- PHT2试验将提供关键数据,以评估针对性心理教育干预措施的有效性,以预防T2D成人严重低血糖症.
- 研究结果将为高风险人群的临床实践和患者自我管理策略提供信息.
相关概念视频
Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156


